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SUMMARY – Th e aim of the study was to determine the infl uence of RET, p27 and cyclin D1 
on regional lymph node metastases in papillary microcarcinoma. Th e analysis included 70 patients 
with papillary thyroid microcarcinoma that underwent surgery at Split University Hospital Center 
between 1999 and 2001. Immunohistochemistry was performed on formalin-fi xed, paraffi  n-embed-
ded tissue by the RET, p27 and cyclin D1 antibodies. Quantifi cation was based on the intensity and 
distribution of nuclear staining, dividing tumors into those that showed expression (expressors) and 
those that showed no expression (non-expressors). Univariate analysis using χ²-test and Fisher exact 
test was performed with the level of statistical signifi cance set at p<0.05. Th ere was no statistically 
signifi cant diff erence in the incidence of metastases according to the expression or non-expression of 
RET mutation (χ²-test: p=0.459; Fisher exact test: p=0.672). Among 25 cases with cyclin D1 expres-
sion, 6 had metastases, whereas only 2 of 45 cases with no cyclin D expression had metastases (χ²-test: 
p=0.014; Fisher exact test: p=0.021), indicating that the expression of cyclin D1 is not crucial for the 
development of metastases in lymph nodes. In contrast, analysis of p27 expression showed it to be 
signifi cantly associated with lymph node metastasis because 3 of 45 patients with p27 expression had 
metastases, indicating a statistically signifi cant correlation between p27 expression and lymph node 
metastases (χ²-test: p=0.093; Fisher exact test: p=0.124). Th is study confi rmed the importance of the 
evaluation of RET, p27 and cyclin D1 expression and demonstrated the validity of their application in 
the assessment of microcarcinoma behavior.
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Introduction
“Papillary carcinoma in a size of one centimeter or 
less, composed of papillae or follicles with typical nu-
clei” is the defi nition that Hazard set in 1960 for pa-
pillary microcarcinoma, and it has been accepted by 
the World Health Organization1,2. Some authors have 
recently tended to defi ne this entity as a separate cat-
egory, not as a subtype of papillary carcinoma3. Nu-
merous terms have been used for this entity, describing 
its clinical presentation and histologic features, e.g., 
occult sclerosing carcinoma, nonencapsulated scleros-
ing tumor, occult papillary tumor, and small papillary 
carcinoma4-6. Th e most commonly used term is papil-
lary microcarcinoma, while other terms cannot pre-
cisely describe its behavior. Clinicians often use the 
term occult cancer because cancer is present but has no 
clinical symptoms and is often revealed as an inciden-
tal fi nding4. Th erefore, the term incidental cancer is 
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increasingly used, as it is mostly presented as an inci-
dental clinical or autopsy fi nding3. Th ese frequent inci-
dental autopsy fi ndings, where death was caused by 
some other disease, have led some researchers to con-
sider papillary thyroid tumor smaller than 5 millime-
ters as a normal fi nding7. Fink et al. found incidental 
papillary thyroid cancer in one-third of autopsy cases 
and in 24% of thyroidectomies performed for other 
thyroid diseases5. However, there is some evidence that 
even those cancers smaller than 5 mm can metastasize 
to lymph nodes, and very rarely to distant organs8-10.
In this study, the term metastases or metastatic 
cancer refers only to regional lymph node metastases. 
However, some authors have proposed changing the 
term papillary microcarcinoma into papillary microtu-
mor, with clear exception of those that occur in pa-
tients younger than 19 years and if lymph node metas-
tases are present11.
In this study, we investigated expression of RET, 
p27 and cyclin D1 in papillary thyroid microcarcino-
ma with or without regional lymph node metastases, 
to reveal diff erences in biological profi le due to clinical 
behavior.
Cyclin D1 gene, located on chromosome 11q23, is 
a positive regulator of the cell cycle, allowing for cell 
cycle progression from G1 to S phase12. Tumor sup-
pressor gene p27 is located on chromosome 12p13. It 
encodes the CDK inhibiting nuclear protein and in-
hibits the formation of cyclinD1/cdk complexes dur-
ing G0 and early G1 phases of the cell cycle12. Cyclin 
D1 overexpression and p27 underexpression were 
found in a variety of tumors and were associated with 
increased tumor aggressiveness, incidence of lymph 
node metastases, and poorer prognosis13.
RET proto-oncogene is located on the long arm of 
chromosome 10. In the pathogenesis of papillary thy-
roid cancer, activation of RET includes rearrangement 
or gene redistribution14.
Th e average representation of RET mutations in 
sporadic papillary cancers in adults is 20%-30%; it is 
increased in childhood and young age tumors to up to 
45%-50%, and is highest in cancers in people having 
been exposed to accidental or therapeutic radiation, 
amounting to 50%-80%15.
Materials and Methods
Histologic and immunohistologic analysis includ-
ed 70 patients with papillary thyroid microcarcinoma 
that underwent surgery at Split University Hospital 
Center between 1999 and 2001.
Formalin-fi xed, paraffi  n-embedded, 3-μm thick tis-
sue sections were deparaffi  nized in toluene and rehy-
drated through graded alcohols to water. Endogenous 
peroxidase activity was blocked by 0.5% hydrogen per-
oxide. Antigen retrieval was performed in 10 mmol/L 
citrate buff er (pH 6.0) inside a microwave pressure 
cooker. Slides were immediately placed into a tap wa-
ter bath. Sections were washed in Tris buff ered saline 
(TBS) for 1×5 minutes, placed in diluted normal se-
rum for 10 minutes, and fi nally incubated.
For all three primary monoclonal antibodies, the 
same manufacturer (Novocastra, Newcastle Upon Tyne, 
United Kingdom) was selected: monoclonal antibody 
for RET oncoprotein clone 3F8 P (HIER); p27 pro-
tein monoclonal antibody clone 1B4 P (HIER) W; 
and cyclin D1 monoclonal antibody clone P2D11F11 
P (HIER/Enzyme) W.
Immunohistochemical staining was performed ac-
cording to the manufacturer’s instructions (Novocas-
tra, Vision Bio Systems (Europe), Newcastle Upon 
Tyne, United Kingdom).
Th e intensity of cyclin D1 expression refers only to 
nuclear staining of tumor cells: G0 – total absence; G1 
– faint nuclear staining; G2 – moderate nuclear stain-
ing; and G3 – intense nuclear staining. Tumors with 
grades 0-1 were defi ned as non-expressors. Distribu-
tion was also observed and graded as follows: G1 – fo-
cal, less than 10% of tumor cells; G2 – 10%-50% of 
tumor cells; and G3 – diff use, >50% of tumor cells.
On statistical analysis, tumors were divided into 
those that showed expression (expressors) and those 
that showed no expression (non-expressors). Expres-
sors had moderate or intense nuclear staining with dif-
fuse distribution (Fig. 1), while non-expressors had 
complete absence of staining. If there were tumors that 
showed faint or focal staining in <10% of tumor cells, 
they were also classifi ed as non-expressors16.
Th e expression of p27 was also analyzed according 
to the intensity of nuclear staining. Th e intensity is 
graded as G0-G4: G0 – total absence of staining; G1 
– faint nuclear staining; G2 – moderate nuclear stain-
ing; G3 – intense nuclear staining; and G4 – staining 
as strong as in normal thyroid tissue (Fig. 2). Tumors 
with grades 0-1 were defi ned as non-expressors.
Both staining methods have common control, i.e. 
normal thyroid tissue is positive control for p27 and 
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negative control for cyclin D1. Positive control for cy-
clin D1, but negative for p27 is mantle cell lymphoma17.
Th e presence of RET/PTC was determined by dif-
fuse cytoplasmic staining on normal measuring scale 
(Fig. 3). Th e absence of staining is the absence of the 
investigated mutation.
Ganglion cells of the small intestine were positive 
control18.
Statistical analysis
RET, cyclin D1 and p27 expression was included 
in the univariate analysis using χ2-test to determine 
predictors of lymph node metastases in papillary thy-
roid microcarcinoma. Th e level of statistical signifi -
cance was set at p<0.05. We used Statistical Package 
for the Social Sciences, version 13.0 for Windows 
(SPSS Inc., Chicago, IL, USA).
Results
In the series of 70 microcarcinomas, expression of 
RET mutation was present in 16 (22.9%) cases. Th ere 
was no statistically signifi cant diff erence in the inci-
dence of metastases according to expression or non-
expression of RET mutation (Table 1).
Cyclin D1 was expressed in 25 (35.7%) of 70 pa-
tients. Metastases were present in 6 of 25 cases with 
cyclin D1 expression and in only 2 of 45 cases with no 
cyclin D expression. In this series, it was quite diffi  cult 
to assess statistically signifi cant infl uence (χ²-test: 
p=0.014; Fisher exact test p=0.021) of cyclin D1 ex-
Fig. 1. Expressor: G2 – moderate, easily visible nuclear 
staining; G3 – diff use (cyclin D1, magnifi cation 40x).
Fig. 2. Expressor: G3 – strong nuclear coloration 
(p27, magnifi cation 40x).
Fig. 3. Positive RET, cytoplasmic staining 
(RET, magnifi cation 40x).
Table 1. Incidence of RET mutation in papillary 
microcarcinomas and relationship between RET 







































χ²-test: p=0.459; Fisher exact test: p=0.672
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pression because there were only 2 metastatic cancers 
in the group without cyclin D expression (Table 2).
In the series of 70 microcarcinomas, p27 expression 
was present in 45 (64.3%) cases. In the group with p27 
expression only 3 of them had metastases, indicating a 
statistically signifi cant correlation between p27 ex-
pression and metastatic behavior (χ²-test: p=0.093; 
Fisher exact test p=0.124) (Table 3).
Discussion
Papillary thyroid microcarcinoma is an entity that 
has been very often a subject of debate because the 
common therapeutic protocol requires total thyroidec-
tomy, whereas many studies have shown it to have a 
good prognosis, suggesting that cancer smaller than 5 
mm should be considered as a normal fi nding7. Th is 
extremely favorable prognosis has led to proposals to 
change the term cancer and replace it with the term 
tumor-papillary microtumor, which is more acceptable 
for patients11.
Lymph node metastases are rare, and metastases to 
distant organs are considered to be case reports8,10,11. 
Th ose rare cases have prompted researchers to investi-
gate diff erence in the biological profi le of these meta-
static rarities and to fi nd out how to recognize them in 
order to provide better therapeutic choice and follow 
up. Examining the RET mutation in papillary carci-
noma, Sugg et al. identifi ed it mainly in occult micro-
carcinomas19. In their studies, Soares et al. and Tallini 
et al. showed the RET mutation to be more common 
in small, slow growing tumors, and to potentially serve 
as a favorable prognostic marker20,21.
In our study, 70 patients were selected according to 
the criteria for microcarcinomas3. We studied the 
prevalence of RET mutation, and found it to be pres-
ent in 22.9% of cases (Table 1). Th is result is not in 
accordance with those reported by Sugg et al.19, but 
complies with the average presence of RET mutation 
in sporadic cancers15,22-24. Lymph node metastases were 
present in 8 patients and no statistically signifi cant 
correlation with RET mutation was found (Table 1).
Th e appearance of metastases in microcarcinomas 
led Khoo et al. to evaluate cyclin D1 expression. Th ey 
found cyclin D1 expression to be increased in 90% of 
metastatic cancers and conclude that it is necessary to 
form subgroups of these microcarcinomas at the mo-
lecular level25. In our study, we recorded cyclin D1 ex-
pression in 25 (35.7%) of 70 microcarcinomas, where-
as in the group with lymph node metastases cyclin D1 
expression was present in 6 (75%) of 8 cases (p=0.014) 
(Table 2). Th is percentage was lower than that report-
ed by Khoo et al.25, but is still signifi cant, especially in 
combination with p27 expression.
In our study, 69.4% of microcarcinomas without 
lymph node metastases did not express cyclin D1 (Ta-
ble 2), which is consistent with the study by Kovacs et 
al., who found the majority of microcarcinomas iden-
tifi ed as incidental autopsy fi nding to have low expres-
sion of cyclin D126.
Table 2. Cyclin D1 expression in papillary 
microcarcinomas and relationship between cyclin D1 







































χ²-test: p=0.014; Fisher exact test: p=0.021
Table 3. Expression of p27 in papillary microcarcinomas 
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We also investigated p27 expression in this group 
of microcarcinomas and found it to be expressed in 
63.4% of cases, confi rming the previously described 
fi nding that lymph node metastases showed a statisti-
cally signifi cant correlation with cyclin D1 expression 
and p27 non-expression (p=0.093) (Table 3). Similarly, 
Khoo et al. report on a decreased level of p27 expres-
sion in papillary microcarcinomas with lymph node 
metastases as compared with those without lymph 
node metastases27.
Th ese results confi rmed the importance of evaluat-
ing p27, cyclin D1 and RET expression, suggesting 
their potential usefulness in the evaluation of micro-
carcinoma behavior.
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Sažetak
IZRAŽAJNOST CIKLINA D1, RET I p27 
U PAPILARNOM MIKROKARCINOMU ŠTITNE ŽLIJEZDE
A. Barić, V. Marković, D. Eterović, V. Bedeković, M. Kontić, Lj. Juretić Kuščić, V. Pešutić Pisac i A. Punda
Cilj istraživanja bio je odrediti utjecaj izražajnosti RET, p27 i ciklina D1 na pojavu metastaza u regionalnim limfnim 
čvorovima kod papilarnog mikrokarcinoma štitnjače. U analizu su uključeni histološki uzorci 70 bolesnika podvrgnutih ope-
rativnom zahvatu zbog papilarnog mikrokarcinoma štitnjače u Kliničkom bolničkom centru Split od 1999. do 2001. godine. 
Histološki uzorci papilarnog mikrokarcinoma pohranjeni u parafi nu i fi ksirani formalinom imunohistokemijski su obojani 
pomoću tri monoklonska protutijela: RET, protein p27 i ciklin D1. Izražajnost je opisana prema intenzitetu i raspodjeli 
stanične obojenosti, dijeleći tumore na one koji imaju izražajnost (ekspresori) i one koji ne pokazuju izražajnost (ne-ekspre-
sori). Statistička obrada podataka učinjena je pomoću χ²-testa i Fisherova egzaktnog testa, uz razinu statističke značajnosti 
od p<0,05. Nije uočena statistički značajna razlika u učestalosti metastaza u odnosu na izražajnost RET mutacije (χ²-test: 
p=0,459; Fisherov egzaktni test: p=0,672). U 25 uzoraka bila je prisutna izražajnost ciklina D1, od kojih su metastaze bile 
prisutne u 6 slučajeva, a od 45 uzoraka bez izražajnosti ciklina D1 metastaze su bile prisutne u samo 2 uzorka (χ²-test: 
p=0,014; Fisherov egzaktni test: p=0,021), iz čega proizlazi da ekspresija ciklina D1 nije presudna za razvoj metastaza u 
limfne čvorove. Nasuprot tome, ekspresija p27 značajno je povezana s metastaziranjem, jer su metastaze bile prisutne u 3 od 
45 ispitanika koji su imali povećanu izraažajnost p27 (χ²-test: p=0,093; Fisherov egzaktni test: p=0,124). Ovim istraživanjem 
potvrdili smo važnost evaluacije izražajnosti p27, ciklina D1 i RET kao i vrijednost njihove primjene u procjeni ponašanja 
mikrokarcinoma.
Ključne riječi: Tireoidni tumor, papilarni; Tireoidni karcinom, anaplastični; Ciklin D1; Inhibitor ciklin-ovisne kinaze p27; 
RET protein, humani
